French Biotech Candidate For Cannabis Use Disorder Fails Phase 2B Clinical Trial, Indivior Will Not Exercise Option
Portfolio Pulse from Nina Zdinjak
Aelis Farma's Phase 2B trial for AEF0117, aimed at treating cannabis use disorder, failed to meet its primary and secondary goals. As a result, Indivior PLC, which had an option to license the drug, decided not to exercise this option. Indivior shares saw a slight decline following the news.
September 05, 2024 | 2:27 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Indivior PLC decided not to exercise its option to license Aelis Farma's AEF0117 after the drug failed to meet primary and secondary endpoints in a Phase 2B trial. This decision impacts Indivior's strategic plans in the cannabis use disorder treatment market.
The failure of AEF0117 in the Phase 2B trial directly impacts Indivior's decision not to pursue licensing, affecting its potential expansion in the cannabis use disorder treatment market. This news likely contributed to the slight decline in Indivior's stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80